✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Sapacitabine is an investigational drug.
There have been 9 clinical trials for Sapacitabine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2011.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center, and National Cancer Institute (NCI).
Recent Clinical Trials for Sapacitabine
|Olaparib + Sapacitabine in BRCA Mutant Breast Cancer||AstraZeneca||Phase 1/Phase 2|
|Olaparib + Sapacitabine in BRCA Mutant Breast Cancer||Cyclacel Pharmaceuticals, Inc.||Phase 1/Phase 2|
|Olaparib + Sapacitabine in BRCA Mutant Breast Cancer||Dana-Farber Cancer Institute||Phase 1/Phase 2|